- Home
- RDI vs MREO Comparison
RDI vs MREO Comparison
Compare RDI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | MREO |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United Kingdom |
| Employees | 2005 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 50.3M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RDI | MREO |
|---|---|---|
| Price | $2.17 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 115.6K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $202,988,000.00 | $500,000.00 |
| Revenue This Year | $16.25 | $5,184.20 |
| Revenue Next Year | $4.04 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $0.20 |
| 52 Week High | $2.41 | $2.37 |
Technical Indicators
Market Signals| Indicator | RDI | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 35.49 |
| Support Level | $1.00 | $0.22 |
| Resistance Level | N/A | $0.35 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 62.12 | 11.89 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).